文献速递胸部肿瘤放疗放疗物理与技术

FDG-PET参数预测III期非小细胞肺癌新辅助放化疗后病理缓解及淋巴结清除

FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
PubMed 文献 · Pract Radiat Oncol · 2017-04-19

本回顾性研究纳入44例接受新辅助放化疗后手术的III期非小细胞肺癌患者,评估放化疗前后FDG-PET参数与病理完全缓解(pCR)的关联。

要点

  • MTV和TLG变化及淋巴结FDG-PET参数均无预测价值。

核心结论

  • SUV和SUR可用于预测新辅助放化疗后pCR,SUR参数诊断比值比更高,预测效用可能优于SUVmax。
  • 淋巴结FDG-PET参数与淋巴结pCR无相关性,MTV和TLG变化无预测价值。

研究设计与样本

  • 回顾性研究,纳入44例接受新辅助放化疗后手术的III期非小细胞肺癌患者,均有放化疗前后FDG-PET影像。
  • 测量SUVmax、SUR、MTV和TLG,分析其与pCR及近pCR的关联。

主要发现

  • 原发灶pCR率为29.5%,近pCR率为45.5%。
  • SUVmax平均下降9.2,SUR-纵隔和SUR-肝脏平均下降分别为4.7和3.5。
  • MTV、TLG变化及淋巴结FDG-PET参数与pCR无显著关联。

关键数值与推荐

  • pCR定义为原发灶病理完全缓解,近pCR包括pCR及接近pCR。

临床怎么用

  • 放化疗后FDG-PET的SUVmax和SUR下降幅度可辅助预测原发灶pCR,SUR可能更优。
  • 淋巴结FDG-PET参数不推荐用于预测淋巴结pCR。
  • MTV和TLG变化不宜作为预测pCR的指标。

局限性

  • 回顾性研究,样本量44例,结果需前瞻性验证。
  • MTV和TLG无预测价值可能与全剂量放疗后炎症有关,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pathologic complete response (pCR) following neoadjuvant chemoradiation (CRT) is associated with improved outcomes in stage III non-small cell lung cancer. Conflicting results exist regarding the value of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting pCR. This study evaluated the association between post-CRT FDG-PET and pCR using novel FDG-PET parameters. METHODS AND MATERIALS: This retrospective study included patients treated with CRT and resection. All underwent pre- and post-CRT FDG-PET imaging. Maximum standard uptake value (SUVmax), standard uptake ratio (SUR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. RESULTS: In total, 44 patients were included for review. The majority had cT2 disease (59.0%). Median radiation dose was 60 Gy (45-70.2 Gy). Rate of pCR and near-pCR within the primary lesion was 29.5% and 45.5%, respectively. Average reduction in SUVmax was 9.2, whereas SUR normalized to mediastinum and liver showed mean reductions of 4.7 and 3.5, respectively. No association was found between pCR and either MTV or TLG. Reduction in SUVmax and SUR were significantly associated with increased rate of pCR (P ≤ .02). A threshold of >75% decrease in SUR-liver showed significant association with near-pCR (diagnostic odds ratio [DOR]: 8.3; P = .007). No correlation was found between nodal FDG-PET parameters and nodal pCR. CONCLUSIONS: Our results indicate SUV and SUR have utility in predicting pCR after neoadjuvant CRT. SUR parameters trended toward higher DORs, suggesting improved predictive utility compared with SUVmax. Notably, no association was found with nodal pCR. Furthermore, MTV and TLG changes were not predictive, potentially resulting from inflammation after full-dose radiation, but this warrants further investigation.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Arnett AL, Packard AT, Mara K, et al. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. Pract Radiat Oncol. 2017. PMID: 28733185. doi:10.1016/j.prro.2017.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。